CLARITY PHARMACEUTICALS
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Clarity expands its pipeline with a novel optimised FAP-targeted radiopharmaceutical 2024-12-18 22:03
Copper-67 SAR-bisPSMA updates 2024-10-16 21:03
Positive guidance from the U.S. FDA on 64Cu-SAR-bisPSMA Phase III trial in patients with recurrence of prostate cancer 2024-10-14 21:02
SECuRE trial advances: No dose limiting toxicities and strong preliminary efficacy data in first multi-dose cohort 2024-09-12 21:03
Clarity receives FDA Fast Track Designation for 64Cu-SAR-bisPSMA 2024-08-22 21:04
Additional COBRA results: SAR-bisPSMA detects lesions in the 2-millimetre range 2024-03-08 22:02
Registrational Phase III CLARIFY trial in prostate cancer commences 2023-11-30 22:16
First patient with metastatic prostate cancer to receive 2 doses of Cu-67 SAR-bisPSMA achieves undetectable PSA level 2023-11-30 21:59
Clarity's theranostic prostate cancer trial progresses at the highest dose level cohort 2023-11-29 21:58
Recruitment target achieved for Phase II SAR-Bombesin prostate cancer trial 2023-11-07 21:58
Clarity and PSI kick off SAR-bisPSMA Phase III 2023-10-26 21:00
First patient treated with Cu-67 SAR-Bombesin in theranostic prostate cancer trial 2023-10-03 20:58
First participant treated at the highest dose level in Clarity's theranostic prostate cancer trial 2023-08-25 20:58
Clarity's theranostic prostate cancer trial advances to highest dose level 2023-08-10 20:58
Clarity reaches 50% recruitment milestone for Phase II SABRE prostate cancer trial 2023-07-24 21:02
Positive guidance from US FDA on Cu-64 SAR-bisPSMA Phase III trial in prostate cancer 2023-07-04 20:55
Clarity establishes a US Center of Excellence for Targeted Copper Theranostics 2023-06-28 20:58
Clarity commences COMBAT theranostic prostate cancer trial in the US 2023-06-20 21:03
Clarity's theranostic prostate cancer trial advances to cohort 2 2023-05-24 21:03
US based COBRA diagnostic prostate cancer trial reaches recruitment target 2023-02-09 22:03
1 2 3